(Utkast) Kommisjonens gjennomføringsforordning (EU) …/… om endring av gjennomføringsforordning (EU) nr. 540/2011 med hensyn til forlengelse av godkjenningsperiodene for de aktive stoffene aluminiumsilikat, bifenoks, bromukonazol, klormekvat, dikamba, etofenproks, fluroksypyr, napropamid, nikosulfuron, oksatiapiprolin, parafinolje CAS-nr. 64742-46-7, parafinolje CAS-nr. 72623-86-0, parafinolje CAS-nr. 97862-82-3, propaquizafop, protiokonazol, quizalofop-P-tefuryl, quizalofop-P-etyl, tetrakonazol, tienkarbazon, triallat, triklopyr og valifenalat
Plantevernmidler: forlengelse av godkjenningsperioden for aluminiumsilikat og en rekke andre aktive stoffer i plantevernmidler
Utkast til kommisjonsforordning godkjent av komite (representanter for medlemslandene) og publisert i EUs komitologiregister 18.11.2026
Bakgrunn
(fra kommisjonsforordningen)
(1) The active substances aluminium silicate, bifenox, bromuconazole, chlormequat, dicamba, etofenprox, fluroxypyr, napropamide, nicosulfuron, oxathiapiprolin, paraffin oils, propaquizafop, prothioconazole, quizalofop-P-tefuryl, quizalofop-P-ethyl, tetraconazole, thiencarbazone, tri-allate, triclopyr and valifenalate were approved as active substances for use in plant protection products for a limited period of time and the applications for the renewal of their approvals are currently being evaluated pursuant to Article 14 of Regulation (EC) No 1107/2009.
(2) Commission Directive 2000/10/EC included fluroxypyr in Annex I to Council Directive 91/414/EEC as an active substance until 30 November 2010 and Commission Implementing Regulation (EU) No 736/2011 approved the active substance until 31 December 2021. The approval of fluroxypyr was extended two times, most recently by Commission Implementing Regulation (EU) 2024/2781 until 15 February 2027.
(3) Commission Directive 2006/74/EC included triclopyr in Annex I to Directive 91/414/EEC as an active substance until 31 May 2017 and it was subsequently included in Part A of the Annex to Implementing Regulation (EU) No 540/2011. The approval of triclopyr was extended nine times, most recently by Commission Implementing Regulation (EU) 2025/2316 until 31 March 2027.
(4) Commission Directive 2008/40/EC included nicosulfuron in Annex I to Directive 91/414/EEC as an active substance until 31 December 2018 and it was subsequently included in Part A of the Annex to Implementing Regulation (EU) No 540/2011. The approval of nicosulfuron was extended six times, most recently by Commission Implementing Regulation (EU) 2023/2592 until 31 March 2027.
(5) Commission Directive 2008/44/EC included prothioconazole in Annex I to Directive 91/414/EEC as an active substance until 31 July 2018 and it was subsequently included in Part A of the Annex to Implementing Regulation (EU) No 540/2011. The approval of prothioconazole was extended seven times, most recently by Commission Implementing Regulation (EU) 2025/787 until 31 March 2027.
(6) Commission Directive 2008/66/EC included bifenox in Annex I to Directive 91/414/EEC as an active substance until 31 December 2018 and it was subsequently included in Part A of the Annex to Implementing Regulation (EU) No 540/2011. The approval of bifenox was extended six times, most recently by Implementing Regulation (EU) 2023/2592 until 31 March 2027.
(7) Commission Directive 2008/69/EC included dicamba in Annex I to Directive 91/414/EEC as an active substance until 31 December 2018 and it was subsequently included in Part A of the Annex to Implementing Regulation (EU) No 540/2011. The approval of dicamba was extended six times, most recently by Implementing Regulation (EU) 2023/2592 until 31 March 2027.
(8) Commission Directive 2008/127/EC included aluminium silicate in Annex I to Directive 91/414/EEC as an active substance until 31 July 2018 and it was subsequently included in Part A of the Annex to Implementing Regulation (EU) No 540/2011. The approval of aluminium silicate was extended seven times, most recently by Implementing Regulation (EU) 2025/2316 until 31 March 2027.
(9) Commission Directive 2009/37/EC included chlormequat, propaquizafop, quizalofop-P-tefuryl and quizalofop-P-ethyl in Annex I to Directive 91/414/EEC as active substances until 30 November 2019 and they were subsequently included in Part A of the Annex to Implementing Regulation (EU) No 540/2011. The approvals of chlormequat, propaquizafop, quizalofop-P-tefuryl and quizalofop-P-ethyl were extended three times, most recently by Commission Implementing Regulation (EU) 2023/1757 until 28 February 2027.
(10) Commission Directive 2009/77/EC included etofenprox and tri-allate in Annex I to Directive 91/414/EEC as active substances until 31 May 2021 and they were subsequently included in Part A of the Annex to Implementing Regulation (EU) No 540/2011. The approvals of etofenprox and tri-allate were extended three times, most recently by Implementing Regulation (EU) 2023/2592 until 31 March 2027.